KR20140070901A - Composition for prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera seed as an active ingredient - Google Patents

Abstract

The present invention relates to a composition to prevent and treat metabolic disorders comprising an extract of Nelumbo nucifera seed as an active ingredient. When the extract of Nelumbo nucifera seed of the present invention is processed with differentiated human fat cell and orally administered into a high fat diet Sprague-Dawley based male rat, differentiation of fat cells and expression of related genes are inhibited, thus differentiation into matured fat cells and fat accumulation are inhibited and abdominal fat decrease and blood lipid concentration are significantly improved in the high fat diet rat. Therefore, the extract of Nelumbo nucifera seed can be suitably used as a pharmaceutical composition and a health supplement to prevent and treat metabolic disorders as the active ingredient.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing and treating metabolic diseases containing an extract of green tea and livestock as an active ingredient.

The present invention relates to a method for the production of Nelumbo nucifera seed extract for the prevention and treatment of metabolic diseases.

Metabolic disorders are generally risk factors for cardiovascular disease and are associated with obesity, diabetes, insulin resistance, lipid metabolism disorders, hypertriglyceridemia, increased free fatty acids, decreased high density cholesterol, and hypertension. Are included in metabolic diseases. Metabolic disorders are caused by genetic defects that cause problems in the metabolism of the body. Most genetic defects in metabolic disorders are inherited from parents, and the types of genes responsible for metabolic disorders have been found to vary. The metabolic process refers to a series of processes that convert food taken from the body into energy that can be consumed. The body uses enzymes to make the food into a simple form that can be minced and digested. In addition, another enzyme in the cell plays a role in generating a substance of a type that can not be taken from food, as an energy source. In other words, the genetic defect of metabolic disorders occurs when enzymes required for metabolism can not function normally, or when the amount of enzyme produced by the body is extremely reduced or eliminated. In addition, due to genetic defects, the ingested material does not decompose and becomes toxic in the body, and the body may not be able to supply necessary substances through the metabolic process.

In modern society, obesity is caused by an increase in the amount of fat accumulation in the body due to various causes. The risk of excessive accumulation of fat in the body has been known from the Greek ages. However, Its importance has been assessed as it has become a major problem. Also, treatment and prevention are important because obesity can develop into metabolic diseases such as hypertension, diabetes, heart disease, arteriosclerosis, and hyperlipemia. Recently, nonalcoholic fatty liver disease has been increasing with obesity, diabetes and hyperlipidemia, and it is known that some of them are cirrhosis. Furthermore, since fatty liver is considered to be an early symptom of metabolic disease rather than simple liver disease, the importance of early diagnosis and treatment of fatty liver due to obesity is increasing.

Nelumbo nucifera ) is a plant cultivated in a pond or rice paddy field. Lotus root, lotus leaf, lotus flower, and livestock are widely used for edible and medicinal purposes. Kites contain a variety of physiologically active substances and are reported to contain large amounts of flavonoids and polyphenol compounds such as kaempferol, quercetin and isoquercetin. Yeast has various potentials including antioxidant effect. Therefore, it has the potential of development as a food processing material and a biological resource, but most of it is distributed as simple processed products such as powder, tea, makgeolli and noodles. The consumer is unable to meet the needs of modern consumers. Various parts ranging from kite leaves, roots, stems, flowers, fruits, young eyes and young roots have been used as medicines. Leaves were used to treat diarrhea and to treat diarrhea with licorice. The petals were duller to treat premature ejaculation, and the flower chinbum was used to treat dyspepsia or hemorrhoids. In addition, lotus stems were used for hemostasis in cases of severe ulcers, menstrual or postpartum bleeding. Surgery of flowers has been used for hemorrhoids, premature ejaculation, hemolytic symptoms in which hemoglobin dissolves out of blood cells (hemocyte), or red blood cells in the body. Fruit is duller and used as an anxiety, fever, heart pain, seeds contain alkaloids and flavonoids, so it is used as blood pressure drop, vasodilator and sedative. Kidney seeds lower cholesterol levels, relax the smooth muscle of the uterus, and have been used for digestive disorders, enteritis, chronic diarrhea, spermatorrhoea, insomnia, and heart rate problems.

Nelumbo nucifera seeds are seeds from which the mature fruit husks of the lotus have been removed. They have no smell, taste and taste. The sweet potato contains a large amount of starch and a sugar called raffinose. The pharmacological effect is known to enhance the function of the spleen and stomach, sleep anxiety, skin whitening, inflammation relaxation, and skin wound healing. The effects on metabolic diseases are not well known.

Thus, the inventors of the present invention have studied the function of the extract of the prawn extract by treating the differentiated human adipocytes with a composition containing the extract of the prawn extract as an active ingredient and then orally administering it to the male Sprague-Dawley rats of the high fat diet group. Inhibits the differentiation and fat accumulation of mature lipopolysaccharide by inhibiting adipocyte differentiation and expression of the related gene, and exhibits the effect of lowering the abdominal fat and blood lipid concentration in the rat with high fat diet. Therefore, prevention and treatment for metabolic diseases The present invention has been completed based on this discovery.

The present invention relates to a method for the production of Nelumbo nucifera seed extract as an active ingredient, and to provide a health food for preventing and improving metabolic diseases.

In order to achieve the above object, the present invention yeonjayuk (Nelumbo The present invention provides a pharmaceutical composition for the prevention and treatment of metabolic diseases containing an extract of Nucifera seed as an active ingredient.

The invention also yeonjayuk (Nelumbo The present invention provides a health food for prevention and improvement of metabolic diseases containing an extract of Nucifera seed as an active ingredient.

Yeonjayuk of the present invention (Nelumbo nucifera seed extract inhibits the differentiation of adipocytes and expression of related genes to inhibit differentiation and fat accumulation into mature adipocytes and significantly improves abdominal fat and blood lipid levels in rats with high fat diet, A pharmaceutical composition for preventing and treating diseases, and an active ingredient of a health food.

Brief Description of the Drawings Figure 1 is a graph showing the effect of the extract of green tea on lipid accumulation in differentiated human adipocytes.
2 is a graph showing the effect of the extract of green tea on the expression of PPAR-γ, leptin and GLUT4 in human adipocytes.
FIG. 3 is a graph showing changes in fat tissue of rats fed with pituitary extract to high fat diet group rats.
a, b, and c: Duncan's multiple range test after one-way ANOVA showed significant difference at p <0.05 in post-test.
FIG. 4 is a graph showing blood lipid changes in rats after feeding a high fat diet group rats with a pituitary extract.
a, b, and c: Duncan's multiple range test after one-way ANOVA showed significant difference at p <0.05 in post-test.

Hereinafter, the present invention will be described in detail.

The present invention relates to a method for the production of Nelumbo The present invention provides a pharmaceutical composition for the prevention and treatment of metabolic diseases containing an extract of Nucifera seed as an active ingredient.

The fruit juice extract as an active ingredient of the present invention is preferably, but not limited to, prepared by a method comprising the steps of:

1) extracting pectin by adding an extraction solvent;

2) filtering the extract of step 1);

3) concentrating the filtrate of step 2) under reduced pressure; And

4) drying the concentrate of step 3).

In the production method of the present invention, the livestock meat of step 1) may be cultivated or commercially available.

In the production method of the present invention, it is preferable to use water, an alcohol or a mixture thereof as the extraction solvent in the step 1). As the alcohol, C ₁ to C ₂ lower alcohols are preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhelt extraction or reflux extraction, but not limited thereto. The extraction solvent is preferably added by 1 to 10 times the amount of the dried soft flesh, more preferably by 2 to 3 times the extraction. The extraction temperature is preferably 20 ° C to 100 ° C, and most preferably 20 ° C to 50 ° C, but is not limited thereto. The extraction time is preferably 1 to 48 hours, more preferably 2 to 10 hours, most preferably 2 to 5 hours, but is not limited thereto. The number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, more preferably 3 times, but is not limited thereto.

In the production method of the present invention, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.

The metabolic disease may be any one selected from the group consisting of obesity, diabetes, fatty liver, hyperlipidemia, and arteriosclerosis, but is not limited thereto.

In order to confirm the efficacy of the pomegranate extract of the present invention as a composition for the prevention and treatment of metabolic diseases, an extract was obtained by using alcohol as a solvent or a mixture thereof as a solvent (see Example 1).

 In addition, in order to examine the effect of the present invention on the prevention and treatment of abdominal obesity, which is one of the metabolic diseases of the present invention, when the extract of the present invention is applied to differentiated human adipocytes, (See Fig. 1). In general, the differentiation from adipocyte precursor cells into mature adipocytes leads to complicated steps and promotes the expression of various related regulators. One of the pivotal roles in this differentiation process is the peroxisome proliferator-activated receptor-gamma (PPAR-γ), a gene transcription regulator. PPAR-γ controls the expression of genes responsible for the differentiation of adipocytes. Glucose transporter 4 (GLUT4) and leptin are known as markers in the final stage of adipocyte differentiation. The effect of the present invention on the expression of transcription factors involved in adipocyte formation such as PPAR-γ and the expression of adipocyte marker genes such as GLUT4 and leptin was observed (see FIG. 2).

In addition, the extract of the present invention was orally administered to Sprague-Dawley male rats in a high fat diet group and the weight of fat tissue was measured. As a result, epididymal fat mass was significantly higher in the high fat diet group than in the normal fat group, , And the amount of retroperitoneal fat was significantly higher in the high fat diet group and the soft fat arm group than in the normal diet group (see FIG. 3).

The total cholesterol content of the high fat diet group was significantly higher than that of the normal diet group, whereas the soft fat arm diet was higher in the high fat diet group than in the normal diet group, as a result of oral fat administration of the extract of the present invention to male Sprague-Dawley rats The triglyceride content of the high fat dietary group was significantly higher than that of the normal dietary group, but it was significantly lower in the soft arm group than in the normal dietary group and the high fat dietary group (see FIG. 4).

Therefore, the extract of the pineal gland of the present invention inhibits the differentiation of adipocytes and expression of related genes, inhibits differentiation into adipocytes and inhibits fat accumulation, and exhibits an effect of lowering abdominal fat and improving blood lipid concentration in a high fat diet- And may be useful as a composition for preventing and treating metabolic diseases.

The compositions of the invention may be administered orally or parenterally (e. G., Coated or intravenously, subcutaneously, or intraperitoneally), but oral administration is preferred. As the agent for parenteral administration, the external preparation such as powders, granules, tablets, capsules, sterilized aqueous solutions, liquid preparations, non-aqueous solutions, suspensions, emulsions, syrups, suppositories and aerosols, The composition may be formulated in the form of a cream, a gel, a patch, a spray, an ointment, a warning agent, a lotion, a liniment, a pasta or a cataplasm. However, the present invention is not limited thereto. The composition for topical administration may be anhydrous or water-based, depending on the clinical formulation. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like. Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, and the like. Examples of liquid formulations for oral use include suspensions, solutions, emulsions, syrups and aerosols. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances and preservatives .

The composition may be prepared by incorporating at least one pharmaceutically acceptable carrier in addition to the active ingredients for parenteral administration for administration. The pharmaceutically acceptable carrier may be a mixture of saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, an antioxidant, , And other conventional additives such as a bacteriostatic agent may be added. In addition, a diluent, a dispersant, a surfactant, a binder, and a lubricant may be additionally added to formulate the composition for injectable use such as an aqueous solution, a suspension or an emulsion.

The pharmaceutically acceptable additives according to the present invention are preferably contained in an amount of 0.1 to 90 parts by weight based on the composition.

The preferred dosage of the composition of the present invention varies depending on the degree of absorption of the active ingredient in the body, the age of the patient, the sex, and the degree of obesity, but can be appropriately selected by those skilled in the art. However, in order to obtain the desired effect, in the case of an oral administration agent, it is generally practiced to administer the composition of the present invention to an adult at a dose of 0.0001 to 100 mg / kg per day, preferably 0.001 to 100 mg / kg per kilogram of body weight per day good. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

The composition for treating metabolic diseases of the present invention may contain one or more active ingredients which exhibit the same or similar functions in addition to the pome fruit extract.

In addition, the present invention provides a health food for prevention and improvement of metabolic diseases containing an extract of pomegranate juice as an active ingredient.

The fruit juice extract as an active ingredient of the present invention is preferably, but not limited to, prepared by a method comprising the steps of:

1) extracting pectin by adding an extraction solvent;

2) filtering the extract of step 1);

3) concentrating the filtrate of step 2) under reduced pressure; And

4) drying the concentrate of step 3).

In the production method of the present invention, the livestock meat of step 1) may be cultivated or commercially available.

In the production method of the present invention, it is preferable to use water, an alcohol or a mixture thereof as the extraction solvent in the step 1). As the alcohol, C ₁ to C ₂ lower alcohols are preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhelt extraction or reflux extraction, but not limited thereto. The extraction solvent is preferably added by 1 to 10 times the amount of the dried soft flesh, more preferably by 2 to 3 times the extraction. The extraction temperature is preferably 20 ° C to 100 ° C, and most preferably 20 ° C to 50 ° C, but is not limited thereto. The extraction time is preferably 1 to 48 hours, more preferably 2 to 10 hours, most preferably 2 to 5 hours, but is not limited thereto. The number of times of extraction is preferably 1 to 5 times, more preferably 3 to 4 times, more preferably 3 times, but is not limited thereto.

In the production method of the present invention, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.

The metabolic disease may be any one selected from the group consisting of obesity, diabetes, fatty liver, hyperlipidemia, and arteriosclerosis, but is not limited thereto.

When the extract of the present invention is fed to rats along with high fat diet, it exhibits the effect of reducing body weight, reducing abdominal fat, and exhibiting lipid-lowering effect in blood, so that the extract of prawn is used as a health food for prevention and improvement of metabolic diseases .

The pomegranate extract of the present invention can be provided as a food composition by mixing with a pharmaceutically acceptable carrier.

When the pomegranate extract of the present invention is used as a food or beverage additive, the pomegranate extract may be directly added or used together with other food or food ingredients, and may be suitably used according to a conventional method. The mixing amount of the livestock meat extract may be suitably determined according to its use purpose (prevention, health or therapeutic treatment). In the case of long-term intake for the purpose of health and hygiene, or for the purpose of controlling health, the above-mentioned extract of the pomegranate is safe and can be taken for a long period of time. There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, soups, drinks, tea, , Alcoholic beverages and vitamin complexes. When formulated into beverage, the liquid ingredient to be added in addition to the extract of prawn extract is not limited to any one, but may include various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of such natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as those commonly used in dextrin and cyclodextrins, , Sorbitol, and erythritol. The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention. Natural flavors such as taumarin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (e.g., saccharin, aspartame, etc.) can be used as flavors other than those described above .

In another aspect, the food composition of the present invention may be formulated into various flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. The food composition of the present invention may also contain pulp for the production of fruit and vegetable drinks. These components may be used singly or in combination, and the proportion of such additives is generally selected in the range of 0.001 to 50 parts by weight based on the total weight of the composition.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Production Examples.

However, the following Examples, Experimental Examples and Preparation Examples illustrate the present invention concretely, and the contents of the present invention are not limited by Examples, Experimental Examples and Production Examples.

< Example  1> Mature meat  Preparation of extract

After 1.4 kg of dry poultry meat (purchased from Siheung City, Gyeonggi-do) was finely crushed, it was extracted with 7 liters of 70% ethanol at a rate of 2.0 g / 100 ml for 2 hours in a hot water bath at 50 ° C. The extract was filtered under reduced pressure, After removing water using a rotary vacuum evaporator, the dried product was subjected to a drying process to obtain a total of 96.4657 g at a yield of 6.83%. In the following <Experimental Example 2>, a dry sample is mixed with 400 mg / kg body weight in saline and then orally administered.

< Experimental Example  1> Mature meat  Identification of the differentiation and fat accumulation inhibitory effects of the extract on fat cells

<1-1> Confirmation of inhibitory effect on lipid differentiation

In order to confirm the effects of the extracts of pine needle cultures on adipocyte differentiation, human adipocyte was induced to differentiate into human adipocyte, and the effect of ethanol extract of soft - .

The cells were grown in 6-well plates using human preadipocyte growth medium kit (Cell Applications Inc., USA) in a human preadipocyte (Cell Applications Inc., USA) 1.8 Cells of × 10 ⁵ cells / well were dispensed in 2 ml portions and cultured in a cell incubator in which carbon dioxide was supplied at 37 ° C and 5% until confluent state was obtained. The adipocyte differentiation medium (Cell Applications Inc., USA) was used to culture the adipocyte precursor cells for adipocyte differentiation and cultured for 2 weeks. Then, the ethanol extract of the present invention was treated at different concentrations of 0, 25, 50 and 100 μg / ml to induce differentiation into adipocytes, thereby confirming the effect of inhibiting adipocyte differentiation. In addition, fat accumulation was confirmed by staining Oil red O in differentiated adipocytes. The differentiated adipocytes were fixed with 10% formaldehyde phosphate buffered saline for 1 hour, and the cells were washed with phosphate buffered saline (PBS). The fixed cells were stained with 60% isopropanol solution with Oil Red O (Sigma, USA) for 2 hours. The cells stained with red granules in the cytoplasm were regarded as differentiated adipocytes and observed using an optical microscope and photographed. In addition, the cells were dyed with Oil Red O dissolved in isopropanol solution, and the absorbance was measured at 510 nm using an absorbance spectrometer.

As a result, as shown in Fig. 1, it was confirmed that the fat pool was decreased in a concentration-dependent manner in the experimental group to which the ethanol extract of mature flesh was added (Fig. 1A). In order to quantitatively investigate lipid accumulation, it was confirmed that the lipid accumulation was decreased due to the decrease of the absorbance in a concentration-dependent manner as a result of measuring the absorbance after dissolving the oil red O dyeing component stained with lipid spheres (FIG. 1B) .

<1-2> Confirmation of gene expression-related inhibitory effect on lipogenesis

In order to confirm the effect of suppressing lipogenesis-related gene expression in extracts of prawn cultures, the fat-derived extracts of the cultured extract of livestock of Example <1-1> were cultured in differentiated adipocytes using an RT-PCR method (TAKARA cDNA synthesis kit) The relative gene expression levels were compared. For this purpose, the total RNA was extracted from the differentiated adipocytes obtained by treating the extracts of livestock meat with different concentrations using a Trizol (Invitrogene, USA) reagent. After isolating the total RNA, the first strand cDNA was reverse transcribed using a random primer (random 9 mers) (5 min at 95 ° C, 60 min at 42 ° C, 10 min at 72 ° C) (45 cycles of 45 seconds at 95 ° C, 45 seconds at 55 ° C and 45 seconds at 72 ° C (28 cycles), 45 seconds at 95 ° C, 45 seconds at 59 ° C and 72 ° C using the PPAR- Leptin and GLUT4 genes were amplified with 45 sec (35 cycles), GLUT4 gene; 45 sec at 95 ° C, 45 sec at 62 ° C and 35 sec at 72 sec. The amplified cDNA of 1 was PCR-amplified using primers of SEQ ID NOS: 1 to 8 shown in the following Table 1, electrophoresed on 1.5% agarose gel, stained with EtBr, Respectively.

As a result, as shown in Fig. 2, the peroxisomegaly factor-activated receptor-gamma (PPAR-gamma), leptin and glucose transporter 4 (GLUT4) It was confirmed that the expression of gene mRNA was inhibited in the treatment of pine needle extract at a concentration of 100 μg / ml (FIG. 2).

< Experimental Example  2> Mature meat  Identification of the efficacy of the extract in vivo

Sprague-Dawley male rats (4 weeks old) were purchased (Koatech, Korea) for 1 week to adjust the in vivo effects of the prawn extract of the present invention. (10 rats) and litter army (10 rats) were randomly assigned to high fat diet group (10 rats) for 7 weeks. The litter army was orally administered daily at a level of 400 mg / kg body weight of ethanol extract of mature flesh for 7 weeks. The basic composition of the experimental diet used in the present invention was prepared based on AIN-93 as shown in Table 2 (Table 2).

< Experimental Example  3> Mature meat  Identification of inhibitory effect of extract on fat accumulation

In order to confirm the effect of suppressing the fat accumulation of the prawn extract, the experimental animals of Example 2 were autopsied and the abdominal fat was extracted and compared. The blood of the experimental animals was fasted for 12 hours before the end of the experiment period and then anesthetized with ether to collect blood from the heart. The collected blood was centrifuged at 3000 rpm for 20 minutes in a centrifuge tube, and the serum was separated and kept frozen at minus 70 ° C until analysis. Immediately after collecting blood according to the above method, epididymal fat and retroperitoneal fat were separated and weighed.

As a result, as shown in FIG. 3, the epinephrine fat mass was significantly higher in the high fat diet group than in the normal fat group, but the soft fat arm group was significantly lower than the high fat diet group, (Fig. 3).

< Experimental Example  4> Mature meat  Identification of the effect of extract on blood lipid concentration

In order to confirm the effect of improving the lipid concentration of the prawn extract, the lipid concentration of the separated serum was measured and confirmed by the method of <Experiment 3>. The serum lipid concentration was measured using an automatic analyzer (Kuadro, Italy) for the concentration of triglyceride and total cholesterol.

As a result, as shown in FIG. 4, the total cholesterol content of the high-fat diet group was significantly higher than that of the normal diet group, but that of the soft fat arm group was significantly lower than that of the high fat diet group and the triglyceride content of the high fat diet group was in the normal diet (Fig. 4). However, it was significantly lower than that of the normal group and the high-fat group (Fig. 4).

< Manufacturing example  1> Preparation of pharmaceutical preparations

<1-1> Sanje  Produce

2 g of the prawn extract of the present invention

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of tablets

100 mg of the pine nut extract of the present invention

Corn starch 100 mg

100 mg of milk

2 mg of magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

100 mg of the pine nut extract of the present invention

Corn starch 100 mg

100 mg of milk

2 mg of magnesium stearate

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

&Lt; 1-4 >

1 g of the prawn extract of the present invention

Lactose 1.5 g

Glycerin 1 g

0.5 g of xylitol

After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.

<1-5> Preparation of granules

150 mg of the pomegranate extract of the present invention

Soybean extract 50 mg

200 mg of glucose

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 to form granules, which were then filled in a capsule.

< Manufacturing example  2> Manufacturing of food

<2-1> Manufacture of confectionery products

0.5-5.0 parts by weight of the extract of the pine needle of the present invention was added to wheat flour and the mixture was used to prepare breads, cakes, cookies, crackers and noodles to prepare foods for health promotion.

<2-2> Manufacture of dairy products

5 to 10 parts by weight of the pomegranate extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<2-3> Solar  Produce

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The pomegranate extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, dried by spraying, and dried in a hot-air drier, and pulverized to a size of 60 mesh with a pulverizer to obtain a dry powder. The dry powders of the cereal grains, seeds, and prawn extracts prepared above were blended in the following proportions.

(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

The dried powder (3 parts by weight) of the pine needle extract of the present invention,

(0.5 part by weight), and rhizome (0.5 part by weight)

< Manufacturing example  3> Manufacturing of beverage

1000 mg of the pine nut extract of the present invention

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 ° C for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, It is used in the manufacture of health food of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (8)

Nectarine ( Nelumbo nucifera seed extract as an active ingredient for the prevention and treatment of metabolic diseases.
2. The method of claim _1, To C ₂ lower alcohol, or a mixed solvent thereof.
[Claim 3] The pharmaceutical composition according to claim 2, wherein the lower alcohol is ethanol or methanol.
The pharmaceutical composition according to claim 1, wherein the metabolic disease is any one selected from the group consisting of obesity, diabetes, fatty liver, hyperlipidemia, and arteriosclerosis.
A health food for prevention and improvement of metabolic diseases containing extract of green tea as an active ingredient.
The method of claim 5, wherein the extract is C ₁ yeonjayuk To C ₂ lower alcohol or a mixed solvent thereof.
The health food for preventing and improving metabolic diseases according to claim 2, wherein the lower alcohol is ethanol or methanol.
[Claim 6] The health food according to claim 5, wherein the metabolic disease is any one selected from the group consisting of obesity, diabetes, fatty liver, hyperlipidemia and arteriosclerosis.

Images